|
|
 Previous Article | Table of Contents | Next Article 
New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic
myelogenous leukemia
G Saglio, A Guerrasio, C Rosso, A Zaccaria, A Tassinari, A Serra, G Rege- Cambrin, U Mazza and F Gavosto
Dipartimento di Scienze Biomediche e Oncologia Umana, Universita di Torino,
Italy.
A new and rare type of Bcr/Abl junction between exon C3 of the 3' portion
of the Bcr gene and Abl exon 2 has been identified in the leukemic cells of
two Ph1-positive chronic myelogenous leukemia patients in chronic phase.
This is the fourth type of Bcr/Abl junction so far identified in
Ph1-positive hematologic malignancies and is a consequence of an unusual
breakpoint position on chromosome 22 that falls approximately 20 kb
downstream of the major breakpoint cluster region (bcr) of the Bcr gene.
The new hybrid mRNA is 540 base pairs (bp) longer than that expressed by
the K562 cell line and could codify for a Bcr/Abl protein carrying 180
additional aminoacids with respect to the larger P210 protein so far
identified. The hematologic phenotype expressed by the two patients
carrying this unusual type of Bcr/Abl rearrangement does not significantly
differ from that commonly seen in chronic myelogenous leukemia.
Volume 76,
Issue 9,
pp. 1819-1824,
11/01/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B C Mondal, S Majumdar, U B Dasgupta, U Chaudhuri, P Chakrabarti, and S Bhattacharyya
e19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases.
J. Clin. Pathol.,
October 1, 2006;
59(10):
1102 - 1103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, G. W. Dewald, M. L. Litzow, J. Cortes, M. J. Mauro, M. Talpaz, and H. M. Kantarjian
Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment
Mayo Clin. Proc.,
March 1, 2005;
80(3):
390 - 402.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. I. Gutierrez, G. Timson, A. K. Siraj, R. Bu, S. Barbhaya, S. Banavali, and K. Bhatia
Single Monochrome Real-Time RT-PCR Assay for Identification, Quantification, and Breakpoint Cluster Region Determination of t(9;22) Transcripts
J. Mol. Diagn.,
February 1, 2005;
7(1):
40 - 47.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Inokuchi, K. Dan, M. Takatori, H. Takahuji, N. Uchida, M. Inami, K. Miyake, H. Honda, H. Hirai, and T. Shimada
Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis
Blood,
July 1, 2003;
102(1):
320 - 323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kurzrock, C. E. Bueso-Ramos, H. Kantarjian, E. Freireich, S. L. Tucker, M. Siciliano, S. Pilat, and M. Talpaz
BCR Rearrangement-Negative Chronic Myelogenous Leukemia Revisited
J. Clin. Oncol.,
June 1, 2001;
19(11):
2915 - 2926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Laurent, M. Talpaz, H. Kantarjian, and R. Kurzrock
The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis
Cancer Res.,
March 1, 2001;
61(6):
2343 - 2355.
[Full Text]
|
|
|
|
|
|
|
K. Katsuki, K. Shinohara, K. Takeda, K. Ariyoshi, T. Yamada, N. Kameda, T. Takahashi, R. Nawata, S. Shibata, Y. Asano, et al.
Chronic Neutrophilic Leukemia with Acute Myeloblastic Transformation
Jpn. J. Clin. Oncol.,
August 1, 2000;
30(8):
362 - 365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Quackenbush, G. W. Reuther, J. P. Miller, K. D. Courtney, W. S. Pear, and A. M. Pendergast
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases
Blood,
May 1, 2000;
95(9):
2913 - 2921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Li, R. L. Ilaria Jr., R. P. Million, G. Q. Daley, and R. A. Van Etten
The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia-like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity
J. Exp. Med.,
May 3, 1999;
189(9):
1399 - 1412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, M. Talpaz, H. M. Kantarjian, and Z. Estrov
Should Polymerase Chain Reaction Analysis to Detect Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Be Used in Clinical Decision Making?
Blood,
May 1, 1999;
93(9):
2755 - 2759.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, H. M. Kantarjian, M. Talpaz, and Z. Estrov
Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia
Blood,
June 1, 1998;
91(11):
3995 - 4019.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yanagisawa, H. Yamauchi, M. Kaneko, H. Kohno, H. Hasegawa, and S. Fujita
Suppression of Cell Proliferation and the Expression of a bcr-abl Fusion Gene and Apoptotic Cell Death in a New Human Chronic Myelogenous Leukemia Cell Line, KT-1, by Interferon-alpha
Blood,
January 15, 1998;
91(2):
641 - 648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Briz, C. Vilches, R. Cabrera, R. Fores, and M. N. Fernandez
Typical Chronic Myelogenous Leukemia With e19a2 Junction BCR/ABL Transcript
Blood,
December 15, 1997;
90(12):
5024 - 5024.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H Mittre, P Leymarie, M Macro, M Leporrier, F Pane, F Salvatore, and G Saglio
A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction. Is it really a distinct disease? [letter]
Blood,
June 1, 1997;
89(11):
4239 - 4240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Wilson, L. Frost, A. Goodeve, E. Vandenberghe, I. Peake, and J. Reilly
BCR-ABL Transcript With an e19a2 (c3a2) Junction in Classical Chronic Myeloid Leukemia
Blood,
April 15, 1997;
89(8):
3064 - 3064.
[Full Text]
[PDF]
|
|
|
|
|
